Takeda Pharmaceutical Company Limited (NYSE:TAK) Q1 2025 Results Conference Call July 31, 2024 6:30 AM ET
Company Participants
Christopher O’Reilly - Head-Investor Relations
Christophe Weber - President and Chief Executive Officer
Milano Furuta - Chief Financial Officer
Andy Plump - President of R&D
Julie Kim - President of U.S. Business Unit
Conference Call Participants
Hiroyuki Matsubara - Nomura Securities
Steve Barker - Jefferies
Shinichiro Muraoka - Morgan Stanley
Mike Nedelcovych - Cowen
Seiji Wakao - JPMorgan Chase & Co
Tony Ren - Macquarie
Kasumi Haruta - UBS Investment Bank
Hidemaru Yamaguchi - Citigroup
Miki Sogi Sanford - Bernstein
Christopher O’Reilly
Thank you very much for taking time out of your very busy schedule to join us for this first quarter earnings call by Takeda for FY ‘24. I’m the master of ceremony today. My name is O’Reilly from IR, I’m the Head of IR.
I would like to explain the language setting first. Please find the language button at the bottom on the Zoom window. If you wish to listen in Japanese, please select the Japanese; if English, please select the English. If you want to listen to the original, please turn them off.
Before starting, I would like to remind everyone that we’ll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in the most recent Form 20-F and in our other SEC filings.
Please also refer to the important notice on Page 2 of the presentation regarding forward-looking statements and our non-IFRS final measures, which will be also discussed during this call. Definitions of our non-IFRS measures and their reconciliations with the comparable IFRS financial measures are included in the appendix of the presentation.
Now without further ado, we would like to move on to the presentation of the day, which will be given by Christophe Weber, President and CEO; Milano Furuta, Chief Financial Officer; and Andy Plump, R&D President. Following the presentations, we have the time for Q&A.
Now let us begin. Christophe, over to you.
Christophe Weber
Thank you, Chris, and thank you, everyone, for joining us today. It’s a pleasure to be with you all.
Overall, we had a very positive start to fiscal year 2024. In the first 3 months, revenue grew 2.1% at constant exchange rate. Performance was driven by the continued strong momentum of our Growth & Launch Products, which grew 17.8% at constant exchange rate, and they now represent 46% of our total revenue.